TP53 and hepatocellular carcinoma: SIRT7 was found to be upregulated in HCC cells and a novel mechanism was identified supporting HCC resistance to therapy, as SIRT7 suppression increased doxorubicin-induced p53 activation through increased acetylation while inhibiting tumor growth and inducing apoptosis [192].